TITLE

Novartis Pulls Out of India

AUTHOR(S)
S. H.
PUB. DATE
October 2007
SOURCE
Pharmaceutical Executive;Oct2007, Vol. 27 Issue 10, p26
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that Novartis AG has pulled out its investment plans for the Gleevec drug from India to China due to refusal of authorities. The company claimed that the Indian's patent laws do not fulfill World Trade Organization requirements. Novartis was challenging the country to grant a patent to a new form of its leukemia drug Gleevec. It is stated that the court decided to refuse Novartis' Gleevec for it has nothing in itself a new chemical entity.
ACCESSION #
27063351

 

Related Articles

  • Novartis: heeding the shift in the cancer treatment paradigm.  // PharmaWatch: Cancer;May2006, Vol. 5 Issue 5, p13 

    The article reports that Novartis AG has filed for marketing approval for Gleevec, a drug used in treating chronic myelogenous leukemia, gastrointestinal stromal tumors and a number of other malignancies in both the U.S. and Europe. The company seeks an approval based on the positive clinical...

  • Patent Watch. Harrison, Charlotte // Nature Reviews Drug Discovery;Mar2011, Vol. 10 Issue 3, p168 

    The article offers drug patent news briefs in the U.S. The Senate Committee on the Judiciary has passed the bill that aims to bring substantial changes to patent law on February 3, 2011. Kyoto University in Japan and the U.S.-based iPierian Inc. agreed to avert a potential dispute surrounding...

  • Regulations could delay Canadian generics. Baltazar, Amanda // Drug Store News;7/21/2008, Vol. 30 Issue 8, p22 

    The article reports on the possibility that proposed government regulations could delay the approval of generic drugs in Canada. With the implementation of the new regulations, brand-name drug companies can reinstate drug patents and hold multiple patents on each of their products. Jim Keon,...

  • Afinitor gains indication.  // Monthly Prescribing Reference;Dec2010, Vol. 26 Issue 12, pA18 

    The article reports on the accelerated approval received by Novartis AG' Afinitor oral kinase inhibitor in the U.S.

  • TRIALS AND TRIPS-ULATIONS: INDIAN PATENT LAW AND NOVARTIS AG V. UNION OF INDIA. Lee, Linda L. // Berkeley Technology Law Journal;2008 Annual Review, Vol. 23 Issue 1, p281 

    The article focuses on the emerging debate regarding intellectual property rights in India. Novartis AG v. Union of India has grabbed the attention of multinational pharmaceuticals concerned about the generic market and the international community concerned about India's compliance with the...

  • Indian Patent Law: Walking the Line? Sheehe, Johanna // Northwestern Journal of International Law & Business;Spring2009, Vol. 29 Issue 2, p577 

    The article provides an overview of Trade Related Aspects of Intellectual Property Rights Agreement (TRIPS) by the World Trade Organization (WTO). It discusses the significance of Indian culture in the establishment of patent law. It examines the impact of WTO membership on Indian patent law. It...

  • Court dismisses Novartis challenge to Indian patent law. Mudur, Ganapati // BMJ: British Medical Journal (International Edition);8/11/2007, Vol. 335 Issue 7614, p273 

    This article reports on a court ruling on patent law which went against drug company Novartis in India. Novartis was challenging the Indian law that prohibits patents on new forms or new uses of existing medications saying it was a violation of the Indian constitution and does not meet...

  • PRESERVING THE PHARMACY TO THE DEVELOPING WORLD. R. W. // Multinational Monitor;Mar/Apr2007, Vol. 28 Issue 2, p14 

    The article focuses on the issues concerning the pharmaceutical patent law in India. It states that treatment of people with HIV/AIDS in developing countries has depended on the existence of generic antiretroviral drugs (ARVs). Because of this, the World Trade Organization's Agreement on...

  • Sangstat Will Continue to Offer Cyclosporine Therapy.  // Worldwide Biotech;Sep99, Vol. 11 Issue 9, p1 

    Reports the continued offering of a lower cyclosporine therapy of SangStat, The Transplant Company in Fremont, California, in response to Novartis filing a patent infringement lawsuit against SangStat in the United Kingdom. Claims that Novartis has violated the antitrust laws; United States...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics